Mass General Brigham Spins Out AIwithCare to Scale AI-Based Clinical Trial Screening

The company is built around RECTIFIER (RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review), an AI-based screening tool developed by researchers within Mass General Brigham.

Mass General Brigham has launched AIwithCare, a new company formed to commercialize a generative artificial intelligence platform designed to accelerate clinical trial screening and patient recruitment, the health system announced on December 12.

The company is built around RECTIFIER (RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review), an AI-based screening tool developed by researchers within Mass General Brigham. The tool uses generative AI and retrieval-augmented generation to analyze electronic health records (EHRs) and determine patient eligibility for clinical trials by extracting key information from both structured data and unstructured clinical notes.

RECTIFIER was developed through Mass General Brigham’s Accelerator for Clinical Transformation and has been evaluated through multiple studies. A proof-of-concept study published in NEJM AI in June 2024 showed the tool more accurately identified eligible patients for a heart failure trial compared to manual screening. A subsequent randomized, blinded trial of nearly 4,500 patients, published in JAMA in 2025, reported that enrollment rates using RECTIFIER were almost double those achieved through traditional manual processes, without significant differences across race, gender, or ethnicity.

Since those studies, RECTIFIER has expanded across Mass General Brigham with more than 20 active and onboarding use cases spanning cardiology, oncology, gastroenterology, neurology, pathology, and psychiatry. The spinout marks the first company formed from a retrieval-augmented generation AI application developed internally by the health system.

AIwithCare will commercialize the technology through its AIwithCare Studio platform, offering the software to external healthcare systems, hospitals, and clinics seeking to match patients with relevant clinical trials and support research and operational workflows.

RECTIFIER screens EHRs for diagnoses, medications, lab values, and other eligibility criteria, including data embedded in free-text notes that typically require time-intensive manual review by research coordinators. Beyond clinical trials, the tool is also being used at Mass General Brigham for clinical and population health applications, including referral triage, patient phenotyping, and eligibility assessment for care management programs.

Mass General Brigham Innovation facilitated the formation of AIwithCare, supporting licensing, company formation, and intellectual property management. Over the past year, the innovation arm reported more than 1,400 active licenses, over 600 new invention disclosures, and nearly 200 issued U.S. patents.

AIwithCare is led by Alexander “A.J.” Blood, MD, MSc, as CEO and co-founder, with Sandy Aronson serving as president and chief AI officer.

Stay tuned for more such updates on Digital Health News